Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4
Open Access
- 1 February 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (2) , 214-222
- https://doi.org/10.1093/jac/dkh542
Abstract
Objectives: Neutrophils play a crucial role in the control of the Aspergillus fumigatus infection and act in concert with antifungal drugs. This study was undertaken to obtain insights into the possible involvement of Toll-like receptors (TLRs) in the interaction of liposomal amphotericin B (L-AmB; AmBisome) with neutrophils in response to A. fumigatus. Methods: For generation of bone marrow-transplanted mice, irradiated C57BL6 mice were infused with T cell-depleted allogeneic donor cells. For infection, mice were injected intranasally with Aspergillus fumigatus conidia and treated with L-Amb and deoxycholate amphotericin B prophylactically or therapeutically. For TLR-dependent antifungal functions, murine neutrophils were preincubated with antifungals or TLR ligands before the addition of Aspergillus conidia. Results: The results show that: (a) neutrophil activation by Aspergillus occurs through TLR signalling pathways differently affecting the oxidative and non-oxidative mechanisms of the killing machinery; (b) by diverting signalling from TLR-2 to TLR-4, liposomes of AmBisome activate neutrophils to an antifungal state while attenuating the pro-inflammatory effects of deoxycholate amphotericin B; (c) this translates in vivo to the optimization of the AmBisome therapeutic efficacy in mice with aspergillosis. Conclusions: These results provide a putative molecular basis for the reduced infusion-related toxicity of AmBisome and suggest that TLR manipulation in vivo is amenable to the induction of optimal microbicidal activity in the absence of inflammatory cytotoxicity to host cells.Keywords
This publication has 40 references indexed in Scilit:
- Review of Newer Antifungal and Immunomodulatory Strategies for Invasive AspergillosisClinical Infectious Diseases, 2003
- The Antifungal Drug Amphotericin B Promotes Inflammatory Cytokine Release by a Toll-like Receptor- and CD14-dependent MechanismJournal of Biological Chemistry, 2003
- AspergillosisInfectious Disease Clinics of North America, 2002
- AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experienceJournal of Antimicrobial Chemotherapy, 2002
- Toll-like receptors in the induction of the innate immune responseNature, 2000
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996
- Lipid Formulations of Amphotericin B: Recent Progress and Future DirectionsClinical Infectious Diseases, 1996
- Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levelsMycoses, 1995
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990